Biological sciences: Biomedical Sciences, Genetics, Biotechnology or Molecular Life Sciences.
Data Sciences: Bio-informatics, Genetic Epidemiology or Statistical Genetics.
Chemistry: Biochemistry or Nanomedicine.
Medicine: Cardiovascular Medicine, Pharmacology or Cardiothoracic Surgery.
15 PhD students (? 4 years of research experience at time of recruitment)
10 JUNE 2019 18:00h – Europe/Brussels
- Maastricht University (The Netherlands, 2 PhD positions)
- Hannover Medical School (Germany, 1 PhD position)
- King’s College London (United Kingdom, 2 PhD position)
- Claude Bernard Lyon University (France, 1 PhD position)
- Technical University Munich (Germany, 2 PhD positions)
- Humanitas University (Milan, Italy, 2 PhD positions)
- University Hospital Hamburg (Germany, 1 PhD position)
- University of Porto (Portugal, 2 PhD positions)
- Mirabilis Therapeutics BV (Maastricht, The Netherlands, 1 PhD position)
- Miltenyi Biotec (Cologne, Germany, 1 PhD position)
TYPE OF CONTRACT
HOURS PER WEEK
OFFER STARTING DATE
Flexible starting June – December 2019
EU RESEARCH FRAMEWORK PROGRAMME
H2020 / Marie Sk?odowska-Curie Actions / European Training Network
MARIE CURIE GRANT AGREEMENT NUMBER
The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train the next-generation of innovation-minded researchers who are able to explore and translate pathogenic insights, accelerate the development of existing RNA therapeutics, and effectively implement innovative drug delivery systems to improve safety and therapeutic efficacy for the treatment of ischemic heart failure. Academic, clinical and industry partners, covering various disciplines ranging from cardiovascular biology to clinical pharmacology and functional genomics to drug development, have teamed up in the EU.
TRAIN-HEART is the first multidisciplinary programme that, ranging from basic research to late stage preclinical development, delivers important insights in the genomic pathophysiology of ischemic heart failure and studies the therapeutic potential of pre-existing RNA therapeutics in vivo, both naked as well as nanoformulated. TRAIN-HEART focuses on non-coding RNA molecules and non-coding RNA-based mechanisms that are exquisite for the cardiomyocyte to target essential and highly localized biological mechanisms. TRAIN-HEART concentrates on the regulatory non-coding parts of the genome as a main determinant of human diversity contributing to the development of ischemic heart failure. Among non-coding RNAs, the importance of microRNAs and long non coding RNAs has been particularly recognized. Their role in the development of ischemic heart failure is the focus of this network.
The research and training agenda falls into several interconnecting themes:
- Pathogenesis:To elucidate the disease mechanisms contributing to the development ischemic HF at the level of molecular genomics and identify new therapeutic targets.
- Pharmacology:To study the mechanism of action of RNA therapeutics capable of silencing or stimulating ncRNA targets currently in preclinical development for ischemic HF, improve its affinity and specific binding capacity for their targets and assess most tolerable dose and best route of administration.
- Delivery:To design and implement novel drug delivery systems (nanoparticles) for efficient in vivo delivery of two previously identified and IP-protected RNA therapeutics in the (damaged) myocardium.
In addition to undertaking a doctoral research degree, the PhD students will engage in a series of collaborative research and training events to develop advanced skills and expertise in tackling challenges linked developing effective solutions for the personalised treatment of ischemic heart failure.
It is a requirement of the funding that applicants cannot have spent more than 12 months in the country of the hosting institute in the 3 years immediately prior to recruitment.